Ligand Pharmaceuticals Incorporated (LGND)

Market Cap	2.11B
Revenue (ttm)	167.13M
Net Income (ttm)	-4.03M
Shares Out	19.26M
EPS (ttm)	-0.22
PE Ratio	n/a
Forward PE	41.23
Dividend	n/a
Ex-Dividend Date	n/a

Volume	78,783
Open	111.70
Previous Close	111.67
Day's Range	109.58 - 112.27
52-Week Range	67.72 - 129.90
Beta	1.03
Analysts	Strong Buy
Price Target	145.00 (+32.11%)
Earnings Date	May 6, 2025

About LGND

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neurobla...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 18, 1992
• Employees: 68
• Stock Exchange: NASDAQ
• Ticker Symbol: LGND
• Website: https://www.ligand.com

Analyst Forecast

According to 6 analysts, the average rating for LGND stock is "Strong Buy." The 12-month stock price forecast is $145.0, which is an increase of 32.11% from the latest price.

Price Target

$145.0

(32.11% upside)

Analyst Consensus: Strong Buy